{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121810","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.812212+00:00","generated_at":"2026-05-30T04:45:15.235265+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tango reports Q3 loss $29.2M; TNG462 shows durable activity; PRMT5 program advanced","bullets":["TNG462 demonstrated clinical activity across multiple tumor types; 43% ORR in cholangiocarcinoma (n=7); median time on treatment 24 weeks and increasing.","Multiple TNG462 combos planned 1H 2025 with RAS(ON) inhibitors (Revolution Medicines), osimertinib, and pembrolizumab.","TNG908 enrollment stopped due to insufficient CNS exposure in glioblastoma; next-gen brain-penetrant TNG456 enters phase 1/2 1H 2025.","Cash $293M as of Sept 30, 2024; cash runway into 3Q 2026; Q3 net loss $29.2M ($0.27/shr) vs $22.3M ($0.23/shr) year ago.","Maeve Waldron-Lynch, M.D. joins as SVP Head of Clinical Development, bringing late-stage oncology regulatory experience."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121810","json":"https://secwatch.observer/filing/0000950170-24-121810.json","markdown":"https://secwatch.observer/filing/0000950170-24-121810.md","text":"https://secwatch.observer/filing/0000950170-24-121810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024121810/0000950170-24-121810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024121810/tngx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:45:15.235265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}